IRIS Accounts Production v25.1.0.734 08455724 Board of Directors 1.4.24 31.3.25 31.3.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh084557242024-03-31084557242025-03-31084557242024-04-012025-03-31084557242023-03-31084557242023-04-012024-03-31084557242024-03-3108455724ns15:EnglandWales2024-04-012025-03-3108455724ns14:PoundSterling2024-04-012025-03-3108455724ns10:Director12024-04-012025-03-3108455724ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3108455724ns10:SmallEntities2024-04-012025-03-3108455724ns10:AuditExempt-NoAccountantsReport2024-04-012025-03-3108455724ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3108455724ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3108455724ns10:FullAccounts2024-04-012025-03-3108455724ns10:Director22024-04-012025-03-3108455724ns10:Director32024-04-012025-03-3108455724ns10:RegisteredOffice2024-04-012025-03-3108455724ns5:CurrentFinancialInstruments2025-03-3108455724ns5:CurrentFinancialInstruments2024-03-3108455724ns5:ShareCapital2025-03-3108455724ns5:ShareCapital2024-03-3108455724ns5:RetainedEarningsAccumulatedLosses2025-03-3108455724ns5:RetainedEarningsAccumulatedLosses2024-03-3108455724ns5:PlantMachinery2024-04-012025-03-3108455724ns5:PlantMachinery2024-03-3108455724ns5:PlantMachinery2025-03-3108455724ns5:PlantMachinery2024-03-3108455724ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3108455724ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-31
REGISTERED NUMBER: 08455724 (England and Wales)















AQSA AND RYEMEAD PHARMACY LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025






AQSA AND RYEMEAD PHARMACY LIMITED (REGISTERED NUMBER: 08455724)






CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 31 March 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


AQSA AND RYEMEAD PHARMACY LIMITED

COMPANY INFORMATION
for the year ended 31 March 2025







DIRECTORS: Mr E Haq
Mrs Z B Begum
Mr M Ehsan





REGISTERED OFFICE: Quantum Accountancy Ltd
Ashley House
97 London Road
Slough
Berkshire
SL3 7RS





REGISTERED NUMBER: 08455724 (England and Wales)





ACCOUNTANTS: Quantum Accountancy
Chartered Certified Accountants
Ashley House
97 London Road
Slough
Berkshire
SL3 7RS

AQSA AND RYEMEAD PHARMACY LIMITED (REGISTERED NUMBER: 08455724)

BALANCE SHEET
31 March 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 21,096 1,897

CURRENT ASSETS
Stocks 80,000 73,000
Debtors 5 402,300 352,591
Cash at bank and in hand 86,382 112,038
568,682 537,629
CREDITORS
Amounts falling due within one year 6 386,600 343,872
NET CURRENT ASSETS 182,082 193,757
TOTAL ASSETS LESS CURRENT
LIABILITIES

203,178

195,654

CAPITAL AND RESERVES
Called up share capital 210 210
Retained earnings 202,968 195,444
SHAREHOLDERS' FUNDS 203,178 195,654

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

AQSA AND RYEMEAD PHARMACY LIMITED (REGISTERED NUMBER: 08455724)

BALANCE SHEET - continued
31 March 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 July 2025 and were signed on its behalf by:





Mr E Haq - Director


AQSA AND RYEMEAD PHARMACY LIMITED (REGISTERED NUMBER: 08455724)

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2025

1. STATUTORY INFORMATION

Aqsa and Ryemead Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 16 (2024 - 15 ) .

AQSA AND RYEMEAD PHARMACY LIMITED (REGISTERED NUMBER: 08455724)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 March 2025

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 April 2024 13,521
Additions 26,230
At 31 March 2025 39,751
DEPRECIATION
At 1 April 2024 11,624
Charge for year 7,031
At 31 March 2025 18,655
NET BOOK VALUE
At 31 March 2025 21,096
At 31 March 2024 1,897

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 308,342 273,185
Other debtors 93,958 79,406
402,300 352,591

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 243,117 219,509
Taxation and social security 22,892 17,683
Other creditors 120,591 106,680
386,600 343,872